Enfusion Other Liab from 2010 to 2024

ENFN Stock  USD 10.02  0.11  1.09%   
Enfusion Other Liabilities yearly trend continues to be very stable with very little volatility. Other Liabilities is likely to drop to about 411.7 K. During the period from 2010 to 2024, Enfusion Other Liabilities quarterly data regression pattern had sample variance of 3.2 B and median of  576,000. View All Fundamentals
 
Other Liabilities  
First Reported
2010-12-31
Previous Quarter
484.2 K
Current Value
411.7 K
Quarterly Volatility
56.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Enfusion financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enfusion's main balance sheet or income statement drivers, such as Tax Provision of 867 K, Net Interest Income of 1.7 M or Depreciation And Amortization of 5.3 M, as well as many indicators such as Price To Sales Ratio of 4.66, Dividend Yield of 0.0034 or PTB Ratio of 16.74. Enfusion financial statements analysis is a perfect complement when working with Enfusion Valuation or Volatility modules.
  
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.

Latest Enfusion's Other Liab Growth Pattern

Below is the plot of the Other Liab of Enfusion over the last few years. It is Enfusion's Other Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enfusion's overall financial position and show how it may be relating to other accounts over time.
Other Liab10 Years Trend
Slightly volatile
   Other Liab   
       Timeline  

Enfusion Other Liab Regression Statistics

Arithmetic Mean544,129
Geometric Mean541,078
Coefficient Of Variation10.35
Mean Deviation42,495
Median576,000
Standard Deviation56,302
Sample Variance3.2B
Range164.3K
R-Value(0.70)
Mean Square Error1.7B
R-Squared0.50
Significance0
Slope(8,860)
Total Sum of Squares44.4B

Enfusion Other Liab History

2024411.7 K
2023484.2 K
2021538 K
2020430 K

About Enfusion Financial Statements

Enfusion investors utilize fundamental indicators, such as Other Liab, to predict how Enfusion Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Other Liabilities484.2 K411.7 K

Pair Trading with Enfusion

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enfusion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enfusion will appreciate offsetting losses from the drop in the long position's value.

Moving together with Enfusion Stock

  0.67U Unity Software Aggressive PushPairCorr
  0.71DJCO Daily Journal CorpPairCorr
  0.77AI C3 Ai Inc Earnings Call This WeekPairCorr
  0.81BL BlacklinePairCorr
  0.62DT Dynatrace Holdings LLCPairCorr

Moving against Enfusion Stock

  0.71VERB VERB TECHNOLOGY PANY Tech BoostPairCorr
  0.38EGAN eGainPairCorr
  0.34VTEX VTEXPairCorr
The ability to find closely correlated positions to Enfusion could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enfusion when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enfusion - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enfusion to buy it.
The correlation of Enfusion is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enfusion moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enfusion moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enfusion can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Enfusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enfusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enfusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enfusion Stock:
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.27)
Earnings Share
0.04
Revenue Per Share
2.155
Quarterly Revenue Growth
0.154
Return On Assets
0.0592
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.